Evidence map›Paper›PMID 31845320›Full record

ArticleInternational journal of cancer2020

Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53.

Satish K Ramraj, Sugantha P Elayapillai, Richard C Pelikan, Yan D Zhao, Zitha R Isingizwe, Amy L Kennedy, Stanley A Lightfoot, Doris M Benbrook

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Satish K RamrajStephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK.
Sugantha P ElayapillaiStephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK.
Richard C PelikanGenes and Human Disease Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK.
Yan D ZhaoBiostatistics & Epidemiology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK.
Zitha R IsingizweDepartment of Pharmaceutical Sciences, College of Pharmacy, The University of Oklahoma Health Sciences Center, Oklahoma City, OK.
Amy L KennedyDepartment of Pathology, College of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK.
Stanley A LightfootCenter for Cancer Prevention and Drug Development, Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK.
Doris M BenbrookStephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK.ORCID 0000-0001-7606-8245
University of Oklahoma Health Sciences Center · USOklahoma State University Oklahoma City · USOklahoma Medical Research Foundation · US

Funding

Tissue Pathology Shared ResourceP30CA225520 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Wade Williams · 2018 to 2026
$27.1M
Quantitative Analysis Core P30GM110766 · NIGMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI GAFFNEY, PATRICK M · 2014 to 2018
$6.1M
Ovarian Cancer ChemopreventionR01CA196200 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI BENBROOK, DORIS MANGIARACINA · 2015 to 2019
$2.5M
NCI NIH HHS P30 CA225520NCI NIH HHS R01 CA196200NIGMS NIH HHS P30 GM110766
6 · The paper itself

Abstract

Current ovarian cancer maintenance therapy is limited by toxicity and no proven impact on overall survival. To study a maintenance strategy targeted at missense mutant p53, we hypothesized that the release of mutant p53 from mortalin inhibition by the SHetA2 drug combined with reactivation of mutant p53 with the PRIMA-1

Indexed as

AnimalsApoptosisAza CompoundsBridged Bicyclo Compounds, HeterocyclicCell Line, TumorChromansFemaleHSP70 Heat-Shock ProteinsHumansMaintenance ChemotherapyMice, NudeMolecular Targeted TherapyMutationOvarian NeoplasmsThionesTumor Suppressor Protein p532,2-bis(hydroxymethyl)-1-azabicyclo(2,2,2,)octan-3-one(((4-nitrophenyl)amino)(2,2,4,4-tetramethyl thiochroman-6-yl)amino) methane-1-thioneAza CompoundsBridged Bicyclo Compounds, HeterocyclicChromansHSP70 Heat-Shock ProteinsmortalinThionesTP53 protein, humanTumor Suppressor Protein p53high-grade serous ovarian cancermortalinp53PRIMA-1SHetA2

Identifiers

PMID31845320
PMCPMC7297651
OpenAlexW2996458196

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.